Abstract
Objective To investigate the efficacy and safety of tirofiban in non-ST-elevation acute coronary syndrome(NSTE ACS)patients during primary percutaneous coronary intervention(PCI).Methods Eighty two patients with NSTE ACS who underwent primary PCI were randomly divided into two groups which were:the tirofiban+PCI group(n=42)and the primary PCI group(n=40).Tirofiban was predominantly initiated in the catheter laboratory before or during the intervention and maintained for 24～36h(10μg/kg for bolus,followed by 0.15μg/kg.3 min infusion).MACE event,periprocedural complications and platelet counting were investigated at 30 days.Heart function by echo was observed.Results The incidence of the major primary end point(refractory ischemia,new myocardial infarction and death)at 30 days was significantly lower in the tirofiban group than that in the placebo group(9.5%vs 20.0%,P＜0.05).There were also improvements in ST segment depression and the number of ischemic leads in the tirofiban group than those in the placebo group(P＜0.05).There was no major bleeding event happened.There was no statistical difference in platelet counting and EF value between the two groups.Both groups showed no thrombocytopenia.Conclusion Trofiban may further lower the incidence of ischemic event in patients with NSTE ACS on the basis of standard treatments in ACS,and is safe and effective. Key words: Acute coronary syndrome; Tirofiban; Percutaneous coronary intervention
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
